...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract >A double-blind, placebo-controlled trial of ciprofloxacin prophylaxis in patients with acute necrotizing pancreatitis.
【24h】

A double-blind, placebo-controlled trial of ciprofloxacin prophylaxis in patients with acute necrotizing pancreatitis.

机译：环丙沙星预防急性坏死性胰腺炎患者的双盲，安慰剂对照试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The use of prophylactic antibiotics in acute severe necrotizing pancreatitis is controversial. METHODS: Prospective, randomized, placebo-controlled, double-blind study was carried out at Bellvitge Hospital, in Barcelona, Spain. Among 229 diagnosed with severe acute pancreatitis, 80 had evidence of necrotizing pancreatitis (34/80 patients were excluded of the protocol). Forty-six patients without previous antibiotic treatment with pancreatic necrosis in a contrast-enhanced CT scan were randomly assigned to receive either intravenous ciprofloxacin or placebo. Five patients were secondarily excluded, and the remaining 41 patients were finally included in the study (22 patients received intravenous ciprofloxacin and 19 patients placebo). RESULTS: Comparing the 22 with intravenous ciprofloxacin and 19 with placebo, infected pancreatic necrosis was detected in 36% and 42% respectively (p = 0.7). The mortality rate was 18% and 11%, respectively (p = 0.6). No significant differences between both treatment groups were observed with respect to variables such as: non-pancreatic infections, surgical treatment, timing and the re-operation rate, organ failure, length of hospital and ICU stays. CONCLUSION: The prophylactic use of ciprofloxacin in patients with severe necrotizing pancreatitis did not significantly reduce the risk of developing pancreatic infection or decrease the mortality rate. The small number of patients included in this study should be considered.
机译：背景：在急性严重坏死性胰腺炎中使用预防性抗生素存在争议。方法：前瞻性，随机，安慰剂对照，双盲研究是在西班牙巴塞罗那的贝尔维奇医院进行的。在229位被诊断患有严重急性胰腺炎的患者中，有80位有坏死性胰腺炎的证据（34/80位患者被排除在治疗方案之外）。在对比增强的CT扫描中，没有接受抗生素治疗的胰腺坏死的46例患者被随机分配接受静脉环丙沙星或安慰剂治疗。其次排除5例患者，其余41例最终纳入研究（22例接受环丙沙星静脉注射治疗，19例接受安慰剂治疗）。结果：与静脉注射环丙沙星的22例和安慰剂与安慰剂的19例相比，被检出的胰腺坏死分别为36％和42％（p = 0.7）。死亡率分别为18％和11％（p = 0.6）。两组变量之间的变量无明显差异，例如：非胰腺感染，手术治疗，时间和再手术率，器官衰竭，住院时间和重症监护病房。结论：环丙沙星在严重坏死性胰腺炎患者中的预防性使用不能显着降低发生胰腺感染的风险或降低死亡率。应考虑本研究中包括的少数患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号